News | February 29, 2024
Bajaj Healthcare enters into definitive CDMO Agreement for 15 APIs with UK/EU customers
BHL will undertake the development and supply of these molecules
BHL will undertake the development and supply of these molecules
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Subscribe To Our Newsletter & Stay Updated
